The Medical Device Business Journal — Medical Device News & Articles | MassDevice
Novation may have been jilted by Medtronic (NYSE:MDT) in February, but the group purchasing organization hasn’t let any grass grow under its feet in its search for new partners.
The Irving, Texas-based GPO said it signed a two-and-a-half-year deal with German cardiac rhythm device maker Biotronik, hard on the heels of inking another 30-month pact with St. Jude Medical (NYSE:STJ) (also for CRM products).
German cardiac device-maker Biotronik backed the doctors it’s alleged to have paid to switch over to its cardiac rhythm therapy devices, calling charges that it rana pay-to-play scheme in Nevada “flatly wrong and unfair.”
The German medical device giant found itself under scrutiny in the States after a New York Times article this month showed that it managed to convince a hospital in Las Vegas to convert from carrying mostly Boston Scientific Corp. (NYSE:BSX) pacemakers and defibrillators over the course of three years.
MASSDEVICE ON CALL — Alleged Biotronik chicanery prompts calls for feds: German cardiac device maker Biotronik is under the spotlight in Nevada after a New York Times probe of a Las Vegas hospital’s allegedly purchased preference for the company’s pacemakers and defibrillators.
Medtronic Inc. (NYSE:MDT) said results from the Improve HF study demonstrate that select guideline-based outpatient heart failure measures can increase patient survival and might be useful for improving patient quality of care.
The Improve HF (The Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting) study is the largest U.S.-based outpatient heart failure clinical study. The results of the study were published in the journal Circulation.
